Identification of blood-entering components of Anshen Dropping Pills based on UPLC-Q-TOF-MS/MS combined with network pharmacology and evaluation of their anti-insomnia effects and mechanisms.
10.19540/j.cnki.cjcmm.20241216.501
- Author:
Xia-Xia REN
1
;
Jin-Na YANG
2
;
Xue-Jun LUO
3
;
Hui-Ping LI
4
;
Miao QIAO
4
;
Wen-Jia WANG
2
;
Yi HE
3
;
Shui-Ping ZHOU
2
;
Yun-Hui HU
2
;
Rui-Ming LI
3
Author Information
1. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China Tasly Pharmaceutical Group Co., Ltd. Tianjin 300410, China.
2. State Key Laboratory of Chinese Medicine Modernization Tianjin 300193, China Tianjin Tasly Digital Intelligence Chinese Medicine Technology Co., Ltd. Tianjin 300410, China Tasly Pharmaceutical Group Co., Ltd. Tianjin 300410, China.
3. State Key Laboratory of Chinese Medicine Modernization Tianjin 300193, China Tianjin State Key Laboratory of Modern Chinese Medicine Tianjin 300410, China.
4. Tasly Pharmaceutical Group Co., Ltd. Tianjin 300410, China.
- Publication Type:Journal Article
- Keywords:
Anshen Dropping Pills;
UPLC-Q-TOF-MS/MS;
blood-entering component;
insomnia;
network pharmacology
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Tandem Mass Spectrometry/methods*;
Sleep Initiation and Maintenance Disorders/metabolism*;
Mice;
Network Pharmacology;
Male;
Chromatography, High Pressure Liquid;
Humans;
Protein Interaction Maps/drug effects*;
Sleep/drug effects*;
Female;
Adult
- From:
China Journal of Chinese Materia Medica
2025;50(7):1928-1937
- CountryChina
- Language:Chinese
-
Abstract:
This study identified blood-entering components of Anshen Dropping Pills and explored their anti-insomnia effects and mechanisms. The main blood-entering components of Anshen Dropping Pills were detected and identified by UPLC-Q-TOF-MS/MS. The rationality of the formula was assessed by using enrichment analysis based on the relationship between drugs and symptoms, and core targets of its active components were selected as the the potential anti-insomnia targets of Anshen Dropping Pills through network pharmacology analysis. Furthermore, protein-protein interaction(PPI) network, Gene Ontology(GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis were performed on the core targets. An active component-core target network for Anshen Dropping Pills was constructed. Finally, the effects of low-, medium-, and high-dose groups of Anshen Dropping Pills on sleep episodes, sleep duration, and sleep latency in mice were measured by supraliminal and subliminal pentobarbital sodium experiments. Moreover, total scores of the Pittsburgh sleep quality index(PSQI) scale was used to evaluate the changes before and after the treatment with Anshen Dropping Pills in a clinical study. The enrichment analysis based on the relationship between drugs and symptoms verified the rationality of the Anshen Dropping Pills formula, and nine blood-entering components of Anshen Dropping Pills were identified by UPLC-Q-TOF-MS/MS. The network proximity revealed a significant correlation between eight components and insomnia, including magnoflorine, liquiritin, spinosin, quercitrin, jujuboside A, ginsenoside Rb_3, glycyrrhizic acid, and glycyrrhetinic acid. Network pharmacology analysis indicated that the major anti-insomnia pathways of Anshen Dropping Pills involved substance and energy metabolism, neuroprotection, immune system regulation, and endocrine regulation. Seven core genes related to insomnia were identified: APOE, ALB, BDNF, PPARG, INS, TP53, and TNF. In summary, Anshen Dropping Pills could increase sleep episodes, prolong sleep duration, and reduce sleep latency in mice. Clinical study results demonstrated that Anshen Dropping Pills could decrease total scores of PSQI scale. This study reveals the pharmacodynamic basis and potential multi-component, multi-target, and multi-pathway effects of Anshen Dropping Pills, suggesting that its anti-insomnia mechanisms may be associated with the regulation of insomnia-related signaling pathways. These findings offer a theoretical foundation for the clinical application of Anshen Dropping Pills.
